Противоопухолевая активность производных фуллерена и возможности их использования для адресной доставки лекарств

1. Jalbout A.F., Hameed A.J., Trzaskowski B. Study of the structural and electronic properties of 1-(4, 5 and 6-selenenyl derivatives-3-formyl-phenyl) pyrrolidinofullerenes. J Organometal Chem 2007;692:1039–47.

2. Jiao F., Liu Y., Qu Y. et al. Studies on antitumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon 2010;48:2231–43.

3. Nishizawa C., Hashimoto N., Yokoo S. et al. Pyrrolidinium-type fullerene derivativeinduced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radic Res 2009;43:1240–7.

4. Wang J., Chen C., Li B. et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumorbearing mice. Biochem Pharmacol 2006;71:872–81.

5. Liu Y., Jiao F., Qiu Y. et al. Immunostimulatory properties and enhanced TNF-a mediated cellular

6. immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology 2009;20:415102–11.

7. Liu Y., Jiao F., Qiu Y. et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity. Biomaterials 2009;30:3934–45.

8. Meng H., Xing G., Sun B. et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. Acs Nano 2010;4:2773–83.

9. Prylutska S., Burlaka A.P., Klymenko P.P. et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol 2011;2:105–10.

10. Kharisov B.I., Kharissova O.V., Gomez M.J., Mendez U.O. Recent advances in the synthesis, characterization, and applications of fulleropyrrolidines. Ind Eng Chem Res 2009;48:545–71.

11. Mikawa M., Kato H., Okumura M. et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001;12:510–4.

12. Liu J.H., Cao L., Luo P.G. et al. Fullerene-conjugated doxorubicin in cells. Acs Appl Mater Interf 2010;2:1384–9.

13. Montellano A., Da Ros T., Bianco A., Prato M. Fullerene C60 as a multifunctional system for drug and gene delivery. Nanoscale 2011;3:4035–44.

14. Rancan F., Helmreich M., Molich A. et al. Fullerene-pyropheophorbide a complexes as sensitizer for photodynamic therapy: uptake and photo-induced cytotoxicity on Jurkat cells. J Photochem Photobiol B 2005;80:1–7.

15. Boyd P.D., Hodgson M.C., Rickard C.E.F. et al. Selective supramolecular porphyrin/fullerene interactions. J Am Chem Soc 1999;121:10487–95.

16. Nishiyama N., Stapert H.R., Zhang G.D. et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjugate Chem 2003;14:58–66.

17. Rezayat S.M., Boushehri S.V.S., Salmanian B. et al. The porphyrin-fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect. Eur J Med

18. Chem 2009;44:1554–69.

19. Buchachenko A.L., Kuznetsov D.A., Breslavskaya N.N., Orlova M.A. Magnesium isotope effect in enzymatic phosphorylation. J Phys Chem B 2008;112:2548–56.

20. Nikolić N., Vranjes-Ethurić S., Janković D. et al. Preparation and biodistribution of radiolabeled fullerene C60 nanocrystals. Nanotechnol 2009;20:385102.

21. Zhou Z., Lenk R.P., Dellinger A. et al. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconj Chem 2010;21:1656–61.

22. Chaudhuri P., Paraskar A., Soni S. et al. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009;3: 2505–14.

23. Song H., Luo S., Wei H. et al. In vivo biological behavior of 99mTc(CO)3 labelled fullerol. J Radioanal Nucl Chem 2010;285:635–9.

24. Roberts J.E., Wielgus A.R., Boyes W.K. et al. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol Appl Pharmacol 2008;228: 49–58.

25. Zhao B., Yin J.J., Bilski P. et al. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol 2009;241:163–72.

26. Prow T.W., Bhutto I., Kim S.Y. et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340–9.

27. Bejjani R.A., Benezra D., Cohen H. et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005;17:124–32.

28. Мешалкин Ю.П., Бгатова Н.Р. Перспективы и проблемы использования неорганических материалов в онкологии. Ж Сиб Фед Ун-та В 2008;3:248–68.

29. Mroz P., Tegos G.P., Gali H. et al. Photodynamic therapy with fullerenes. Photochem Photobiol Sci 2007;6:1139–49.

30. Burlaka A.P., Sidorik U.P., Pryl 2004;26:326–7.

31. Mroz P., Pawlak A., Satti M. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radical Biol Med 2007;43:711–9.

32. Yano S., Hirohara S., Obata M. et al. Current states and future views inphotodynamic therapy. J Photochem Photobiol C 2011;12:46–67.

33. Hu Z., Zhang C., Huang Y. et al. Photodynamic anticancer activities of water-soluble C60 derivatives nd their biological consequences in a HeLa cell line. Chem Biol Inter 2012;195:86–94.

34. Liu J., Ohta S., Sonoda A. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Controlled Release 2007;117:104–10.

35. Jiang G., Li G. Preparation, characterization, and properties of fullerene–vinylpyrrolidone copolymers. Biotechnol Prog 2012;28:215–22.

36. Vileno B., Jeney S., Sienkiewicz A. et al. Evidence of lipid peroxidation and protein phosphorylation in cells upon oxidative stress photo-generated by fullerols. Biophys Chem 2010;152:164–9.

37. Badireddy A.R., Hotze E.M., Chellam S. et al. Inactivation of bacteriophages via photosensitization of fullerol nanoparticles. Environ Sci Technol 2007;41:6627–32.

38. Taroni P., D’Andrea C., Valentini G. et al. Fullerol in human lens and retinal pigment epithelial cells: time domain fluorescence spectroscopy and imaging. Photochem Photobiol Sci 2011;10:904–10.

39. Straface E., Santini M.T., Donelli G. et al. Vitamin E prevents UVB-induced cell blebbing and cell death in A431 epidermoid cells. Int J Rad Biol 1995;68:579–87.

40. Ito S., Itoga K., Yamato M. et al. The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin. Toxicology 2010;267:27–38.

41. Fumelli C., Marconi A., Salvioli S. et al. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2000;115: 835–41.

42. Zhao B., He Y.Y., Chignell C.F. et al. Difference in phototoxicity of cyclodextrin complexed fullerene [(γ-CyD)2/C60] and its aggregated derivatives toward human lens epithelial cells. Chem Res Toxicol 2009;22:660–7.

43. Mikata Y., Takagi S., Tanahashi M. et al. Detection of 1270 nm emission from singlet oxygen and photocytotoxic property of sugar-pendant 60 fullerenes. Bioorg Med Chem Lett 2003;13:3289–92.

44. Otake E., Sakuma S., Torii K. et al. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. Photochem Photobiol 2010;86:1356–63.

45. Palyvoda K.O., Grynyuk I.I., Prylutsk S.V. et al. Apoptosis photoinduction by C60 fullerene in human leukemic T cells. Ukr Biochem J 2010;82:121–7.

46. Constantin C., Neagu M., Ion R. et al. Fullerene-porphyrin nanostructures in photodynamic therapy. Nanomedicine 2010;5:307–17.

47. Sharma S.K., Chiang L.Y., Hamblin M.R. Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine 2011;6:1813–25.

48. Ni J., Wu Q.Y., Li Y.G. et al. Cytotoxic and radiosensitizing effects of nano-C60 on tumor cells in vitro. J Nanoparticle Res 2008;10:643–51.

49. Andrievsky G., Bruskov V.I., Tykhomyrov A.A., Gudkov S.V. Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic Biol Med 2009;47:786–93.

50. Huang S.Q., Gao Y., Li F. et al. Synthesis of fullerene derivative C(60)-Lys and its radioprotection effects in AHH-1 cell. J Rad Res Rad Proces 2010;1:37–41.

51. Theriot A.C., Casey R.C., Moore V.C. et al. Dendro[C60]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells. Rad Envir Biophys 2010;49:437–45.

52. Chirico F., Fumelli C., Marconi A. et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol 2007;16:429–36.

53. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469–78.

54. Cai X., Hao J., Zhang X. et al. The polyhydroxylated fullerene derivative C60(OH)24 protects mice from ionizingradiation- induced immune and mitochondrial dysfunction. Toxicol Appl Pharmacol 2010;243:27–34.

55. Injac R., Perse M., Cerne M. et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009;30:1184–96.

56. Dordević A., Bogdanović G. Fullerenol – a new nanopharmaceutic? Arch Oncol 2008;16:42–5.

57. Takada H., Kokubo K., Matsubayashi K., O evaluated by β-carotene bleaching assay. Biosci Biotechnol Biochem 2006;70: 3088–93.

58. Vávrová J., Řezáčová M., Pejchal J. Fullerene nanoparticles and their antioxidative effects: a comparison to other radioprotective agents. J Appl Biomed 2012;10:1–8.

59. Fourches D., Pu D., Tassa C. et al. Quantitative nanostructure-activity relationship modeling. Acs Nano 2010;4:5703–12.

60. Kayat J., Gajbhiye V., Tekade R.K., Jain N.K. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomed Nanotechnol Biol Med 2011;7:40–9.

61. Miller J., Lam M., Lebovitz R. Derivatized fullerenes: a new class of therapeutics and imaging agents. HeinOnline. Nanotech. L. & Bus., 2007.

62. Kepley C. Use of fullerenes for the treatment of mast cell and basophil-mediated disease. US Patent, № 7947262, 2006.

63. Kateb B., Chiu K., Black K.L. et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?NeuroImage, 2011;54:106–24.

64. Bystrzejewska-Piotrowska G., Golimowski J., Urban P.L. Nanoparticles: Their potential toxicity, waste and environmental management. Waste Management 2009;29:2587–95.

65. Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 2008;4:26–49.